Home > Insider Trading > Filing (0001615774-19-008214)

Filing Details

Accession Number:: 0001615774-19-008214
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-05-21 20:55:35
Reporting Period:: 2019-05-17

Accepted Time:: 2019-05-21 20:55:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1227254	Bioasia Mangement Llc	192 Lytton Avenue Palo Alto CA 94301		No	No	Yes	No
1261786	Bioasia Investments Iv Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-05-17	1,492	$1.98	9,856	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-05-20	9,856	$1.92	0	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-05-17	10,434	$1.98	68,942	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-05-20	68,942	$1.92	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares of common stock are held directly by Biotechnology Development Fund II, L.P. ("BDF II"). BioAsia Management, LLC is the sole general partner of BDF II, and may be deemed to beneficially own the shares of common stock owned by BDF II. BioAsia Management, LLC disclaims beneficial ownership of the shares of Soleno Therapeutics held by BDF II, except to the extent of its pecuniary interest therein. The voting members of BioAsia Management LLC are Frank Kung, Edgar Engleman and Anselm Leung, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
The shares of common stock are held directly by Biotechnology Development Fund IV, L.P., Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (collectively, "Vivo Fund IV"). BioAsia Investments IV, LLC is the general partner of Vivo Fund IV and may be deemed to be beneficially own such shares. The voting members of BioAsia Investments IV, LLC are Frank Kung and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.89 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.